brodalumab (Siliq)
Jump to navigation
Jump to search
Indications
- moderate-severe psoriasis (FDA-approved Feb 2017)
- psoriatic arthritis
- may be used in conjunction with methotrexate &/or glucocorticoids[2]
Dosage
- injection: 70-280 mg
- psoriatic arthritis:
- 140-280 mg weekly for 1st 2 weeks, then every 2 weeks
* 210 mg SC at weeks 0, 1, & 2, the 210 mg SC every 2 weeks[3]
* continued treatment beyond 16 weeks in patients who have not achieved an adequate response is not indicated[3]
Adverse effects
- dose-dependent neutropenia (reversible)
Mechanism of action
- IL17 receptor A antibody (IgG2 Ab)
More general terms
References
- ↑ Papp KA et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012 Mar 29; 366:1181. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22455412
- ↑ 2.0 2.1 Mease PJ et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014 Jun 12; 370:2295 PMID: https://www.ncbi.nlm.nih.gov/pubmed/4918373
- ↑ 3.0 3.1 3.2 Lowes R FDA Approves Siliq for Psoriasis. Medscape. Feb 15, 2017. http://www.medscape.com/viewarticle/875859
FDA News Release. February 15, 2017 FDA approves new psoriasis drug http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm541981.htm
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Lebwohl M, Strober B, Menter A et al Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015 Oct;373(14):1318-28. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26422722 Free Article